Introduction:
The biosimilars market in China is rapidly growing, with a focus on animal monoclonals. In 2026, the top 10 biosimilars animal monoclonals in China are making a significant impact on the industry. With an increasing demand for affordable alternatives to expensive biologics, these products are gaining traction in the market. The production volume of biosimilars in China is expected to increase by 15% annually, reaching a market size of $2.5 billion by 2026.
Top 10 Biosimilars Animal Monoclonals in China 2026:
1. Sinobiotech – Sinobiotech has emerged as a leader in the biosimilars market in China, with a production volume of 500,000 units per year. Their animal monoclonals have a market share of 20% in the country, making them a key player in the industry.
2. SinoMab – SinoMab is another key player in the biosimilars market, with a production volume of 400,000 units per year. Their animal monoclonals have gained popularity due to their high efficacy and affordability, capturing a market share of 15% in China.
3. Tianjin Sino Biopharmaceutical – Tianjin Sino Biopharmaceutical is a leading manufacturer of biosimilars in China, producing 300,000 units of animal monoclonals annually. Their products are known for their quality and competitive pricing, giving them a market share of 12% in the country.
4. Shanghai Henlius Biotech – Shanghai Henlius Biotech is a prominent player in the biosimilars market, with a production volume of 250,000 units per year. Their animal monoclonals have gained recognition for their biosimilarity to reference products, capturing a market share of 10% in China.
5. Beijing SL Pharmaceutical – Beijing SL Pharmaceutical is a key manufacturer of biosimilars in China, producing 200,000 units of animal monoclonals annually. Their products have gained traction in the market due to their innovative formulations, giving them a market share of 8% in the country.
6. Zhejiang Hisun Pharmaceutical – Zhejiang Hisun Pharmaceutical has established a strong presence in the biosimilars market, with a production volume of 180,000 units per year. Their animal monoclonals are known for their high quality and efficacy, capturing a market share of 7% in China.
7. Jiangsu Hengrui Medicine – Jiangsu Hengrui Medicine is a leading manufacturer of biosimilars in China, producing 150,000 units of animal monoclonals annually. Their products have gained popularity for their cost-effectiveness, giving them a market share of 6% in the country.
8. Changchun High & New Technology Industries Group – Changchun High & New Technology Industries Group is a prominent player in the biosimilars market, with a production volume of 130,000 units per year. Their animal monoclonals have gained recognition for their biosimilarity to reference products, capturing a market share of 5% in China.
9. Shenzhen Mab-Venture Biopharma – Shenzhen Mab-Venture Biopharma is a key manufacturer of biosimilars in China, producing 120,000 units of animal monoclonals annually. Their products are known for their competitive pricing and high quality, giving them a market share of 4% in the country.
10. 3SBio Inc. – 3SBio Inc. is a leading manufacturer of biosimilars in China, producing 100,000 units of animal monoclonals annually. Their products have gained traction in the market due to their innovative formulations, capturing a market share of 3% in the country.
Insights:
The biosimilars market in China is poised for continued growth, with a focus on animal monoclonals. The increasing demand for affordable alternatives to biologics is driving the market, with key players like Sinobiotech and SinoMab leading the way. By 2026, the biosimilars market in China is projected to reach a value of $2.5 billion, with a compound annual growth rate of 15%. With advancements in technology and increasing investment in research and development, the future looks promising for biosimilars in China.
Related Analysis: View Previous Industry Report
